Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2011
Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 October 2019
Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2008
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [TSID12347]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC